News und Analysen

Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more

Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after

Cathie Wood is rolling again. Growth stocks are back in favor, and that's good news for the founder, CEO, and primary investment manager of the Ark Invest family of exchange-traded funds (ETFs).

It took 13 years, 15 nations, and roughly $100 billion to build the International Space Station (ISS). But one company thinks it can build a replacement for as little as $3 billion -- or less.

That

On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Ge

BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news

Even though broader equities have been highly volatile this year, it's still a good idea to invest in stocks for a straightforward reason. Holding shares of top companies for five years and beyond

A new month has arrived. Investors now have a fresh opportunity to buy great stocks. Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. Here's why they

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return

Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an

The past three years have been challenging for Pfizer (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022

More than 100 million Americans use AT&T's (NYSE: T) products and services. So do nearly 2.5 million businesses. How many investors rely on A&T's stock to generate reliable dividend income? I don't

You don't need to uncover the next big artificial intelligence stock to outperform the broader stock market. Sometimes, consistent and profitable growth is all you need to achieve outsize investment

Investors tend to gravitate to growth stocks they perceive as smart. Indeed, the idea of a smart stock can depend heavily on one's point of view.

Still, most would agree that buying a wonderful

Shares of Summit Therapeutics (NASDAQ: SMMT) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.

Summit has been a tremendous winner over the past

When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that

In this video, I will cover the recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

Earlier this year, biotech company 23andMe filed for bankruptcy. The harsh reality was that its business, while enticing to people who wanted to learn about their backgrounds via DNA testing kits

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just 13

The three major indexes slid in March and April as investors worried about the impact of President Donald Trump's import tariffs on the economy -- but in recent weeks, optimism about lower, more

Shares of major semiconductor stocks Broadcom (NASDAQ: AVGO), Advanced Micro Devices (NASDAQ: AMD), and Arm Holdings (NASDAQ: ARM) rallied on Tuesday, rising 3%, 3.9%, and 5.3%, respectively.

Chip

Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

However